Macular Edema and Macular Degeneration Market by Treatment Type (Drug Therapy and Laser Treatment) Application (Macular Edema and Macular Degeneration), and End User (Hospitals, Clinics and Others): Global Opportunity Analysis and Industry Forecast, 2021–2030
- ALL4676823
- 210 Pages
- September 2021
- Diagnostic and Biotech
Macular edema occur after eye surgery, there is abnormal leakage and accumulation of fluid in the macula from damaged blood vessels in the nearby retina that leads to the vision impairment and also might lead to the vision loss. Untreated chronic macular edema can lead to cause macular degeneration. Macular degeneration is a medical condition which may result in no vision or blurred in the center of the visual field. Macular degeneration known as age-related macular degeneration (AMD or ARMD), generally elderly population develop macular edema and macular degeneration because of natural aging process of the body. There are two types of macular degeneration namely dry age-related macular degeneration and wet age-related macular degeneration. Macular edema is categorized into diabetic macular edema (DME) and cystoid macular edema (CME). In addition, the rising population suffering from diabetes, causing diabetic macular edema in the patients will help in driving the growth of the macular edema and macular degeneration market. The macular edema and macular degeneration segment into treatment type, application, and end user. By treatment market is categorized into drug therapy and laser treatment by application market is segmented into macular edema and macular degeneration and by end user hospitals, clinics, and others. Moreover, the high prevalence of age-related macular degeneration and the rising geriatric population is driving the market. Whereas high cost of macular edema and macular degeneration treatment is hampering the market. Furthermore, the major factors attributing to the growth of the macular edema and macular degeneration market are the increasing burden of retinal disorders, upsurge in the geriatric population, and increase in R&D investments.
Based on treatment, the market is segmented into drug therapy and laser treatment. Drug therapy segment accounted for the majority of market share of the global market in 2020. The factors such as increase in prevalence of diabetes patients who have diabetes for many years can develop neuropathy, a reduced or complete lack of vision due to nerve damage and surge in cases of diabetic macular edema (DME) drives the growth of the market.
Based on application, the market is segmented into Macular Edema (diabetic macular edema (DME) and cystoid macular edema (CME) and macular degeneration (dry age-related macular degeneration and wet age-related macular degeneration). Macular degeneration segment accounted for the majority of market share of the global market in 2020 and expected to remain dominant during the forecast period, owing to rise in occurrence of diabetes due to unhealthy lifestyle of people and increasing cases of diabetes. These are the factors which is boosting the market growth.
Based on end user, the market is segmented into hospitals, clinics, and others. The hospital segment accounted for maximum market revenue in 2020 and is anticipated to maintain its dominant position during the forecast period. This is attributed to increase in cases of diabetes and treatment of macular edema and macular degeneration including drug therapy and laser treatment in hospital.
Based on region, the macular edema and macular degeneration market is analyzed across North America, Asia-Pacific, Europe and LAMEA. North America dominated the market in 2020, accounting for the highest share, and is anticipated to maintain this trend throughout the forecast period. This is attributed to the increasing case of Diabetic Macular Edema (DME), Cystoid Macular Edema (CME), Dry age-related macular degeneration and Wet age-related macular degeneration, thus rise in demand for macular edema and macular degeneration treatment to treat these macular edema and macular degeneration is a major factor that contributes toward the growth of the macular edema and macular degeneration market. However, as per macular edema and macular degeneration market forecast, Europe is projected to register the highest growth rate from 2021 to 2030.
This report provides comprehensive competitive analysis and profiles of prominent market players such as F. Hoffmann-La Roche Ltd, Novartis AG, GlaxoSmithKline plc
Allergan, Regeneron Pharmaceuticals Inc., Alimera Sciences, Bausch Health Companies Inc., Kubota Pharmaceutical Holdings Co., Bayer AG and RegenX bio.Tissue Culture Biologicals, Caisson Laboratories, Inc., Cell Culture Technologies LLC and Biomol GmbH and Nucleus Biologics.
KEY BENEFITS FOR STAKEHOLDERS
The study provides an in-depth analysis of the macular edema and macular degeneration market along with the current trends and future estimations to elucidate the imminent investment pockets.
A comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
Comprehensive quantitative analysis of the industry from 2020 to 2030 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
Extensive analysis of the key segments of the industry helps to understand the products and end users of macular edema and macular degeneration market used across the globe.
Key market players and their strategies have been analysed to understand the competitive outlook of the market.
KEY MARKET SEGMENTS
By Treatment Type
• Drug Therapy
• Laser Treatment
By Application
• Macular Edema
o Diabetic Macular Edema (DME)
o Cystoid Macular Edema (CME)
• Macular Degeneration
o Dry age-related macular degeneration
o Wet age-related macular degeneration
By End User
• Hospitals
• Clinics
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o France
o UK
o Italy
o Spain
o Rest of Europe
• Asia-Pacific
o Japan
o China
o Australia
o India
o South Korea
o Rest of Asia-Pacific
• LAMEA
o Brazil
o South Arabia
o South Africa
o Rest of LAMEA
KEY MARKET PLAYERS
• F. Hoffmann-La Roche Ltd
• Novartis AG
• GlaxoSmithKline plc
• Allergan
• Regeneron Pharmaceuticals Inc
• Alimera Sciences
• Bausch Health Companies Inc.
• Kubota Pharmaceutical Holdings Co.
• Bayer AG
• RegenX bio.
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools & models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.CXO perspective
CHAPTER 3:MARKET LANDSCAPE
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.3.Porter’s five force analysis
3.4.Top player positioning, 2020
3.5.Market dynamics
3.5.1.Drivers
3.5.1.1.Increase in aging population
3.5.1.2.Advancements in treatment
3.5.2.Restraints
3.5.2.1.Dearth of skilled professionals
3.5.3.Opportunities
3.5.3.1.R&D investment by pharmaceutical
3.6.Covid-19 Impact analysis on the macular edema and macular degeneration market
CHAPTER 4:MACULAR EDEMA AND MACULAR DEGENERATION MARKET,
4.1.Overview
4.1.1.Market size and forecast, by treatment type
4.2.Drug Therapy
4.2.1.Key trends and growth opportunities
4.2.2.Market size and forecast
4.2.3.Market analysis, by country
4.3.Laser Treatment
4.3.1.Key trends and growth opportunities
4.3.2.Market size and forecast
4.3.3.Market analysis, by country
CHAPTER 5:MACULAR EDEMA AND MACULAR DEGENERATIONMARKET, BY APPLICATION
5.1.Overview
5.1.1.Market size and forecast
5.2.Macular Edema
5.2.1.Market size and forecast
5.2.2.Market analysis, by country
5.2.2.1.Diabetic Macular Edema (DME)
5.2.2.2.Cystoid Macular Edema (CME)
5.3.Macular Degeneration
5.3.1.Market size and forecast
5.3.2.Market analysis, by country
5.3.2.1.Dry age-related macular degeneration
5.3.2.2.Wet age-related macular degeneration
CHAPTER 6:MACULAR EDEMA AND MACULAR DEGENERATIONMARKET, BY END USER
6.1.Overview
6.1.1.Market size and forecast
6.2.Hospitals
6.2.1.Market size and forecast
6.2.2.Market analysis, by country
6.3.Clinics
6.3.1.Market size and forecast
6.3.2.Market analysis, by country
6.4.Others
6.4.1.Market size and forecast
6.4.2.Market analysis, by country
CHAPTER 7:MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY REGION
7.1.Overview
7.1.1.Market size and forecast, by region
7.2.North America
7.2.1.Key trends and growth opportunities
7.2.2.Market size and forecast, by Treatment
7.2.3.Market size and forecast, by application
7.2.4.Market size and forecast, by end user
7.2.5.Market size and forecast, by country
7.2.5.1.U.S.
7.2.5.2.U.S. market size and forecast, by Treatment
7.2.5.3.U.S. market size and forecast, by application
7.2.5.4.U.S. market size and forecast, by end user
7.2.5.5.Canada
7.2.5.6.Canada market size and forecast, by Treatment
7.2.5.7.Canada market size and forecast, by application
7.2.5.8.Canada market size and forecast, by end user
7.2.5.9.Mexico
7.2.5.10.Mexico market size and forecast, by Treatment
7.2.5.11.Mexico market size and forecast, by application
7.2.5.12.Mexico market size and forecast, by end user
7.3.Europe
7.3.1.Key trends and growth opportunities
7.3.2.Market size and forecast, by Treatment
7.3.3.Market size and forecast, by application
7.3.4.Market size and forecast, by end user
7.3.5.Market size and forecast, by country
7.3.5.1.Germany
7.3.5.2.Germany market size and forecast, by Treatment
7.3.5.3.Germany market size and forecast, by application
7.3.5.4.Germany market size and forecast, by end user
7.3.5.5.France
7.3.5.6.France market size and forecast, by Treatment
7.3.5.7.France market size and forecast, by application
7.3.5.8.France market size and forecast, by end user
7.3.5.9.UK
7.3.5.10.UK market size and forecast, by Treatment
7.3.5.11.UK market size and forecast, by application
7.3.5.12.UK market size and forecast, by end user
7.3.5.13.Italy
7.3.5.14.Italy market size and forecast, by Treatment
7.3.5.15.Italy market size and forecast, by application
7.3.5.16.Italy market size and forecast, by end user
7.3.5.17.Spain
7.3.5.18.Spain market size and forecast, by Treatment
7.3.5.19.Spain market size and forecast, by application
7.3.5.20.Spain market size and forecast, by end user
7.3.5.21.Rest of Europe
7.3.5.22.Rest of Europe market size and forecast, by Treatment
7.3.5.23.Rest of Europe market size and forecast, by application
7.3.5.24.Rest of Europe market size and forecast, by end user
7.4.Asia-Pacific
7.4.1.Key trends and growth opportunities
7.4.2.Market size and forecast, by Treatment
7.4.3.Market size and forecast, by application
7.4.4.Market size and forecast, by end user
7.4.5.Market size and forecast, by country
7.4.5.1.Japan
7.4.5.2.Japan market size and forecast, by Treatment
7.4.5.3.Japan market size and forecast, by application
7.4.5.4.Japan market size and forecast, by end user
7.4.5.5.China
7.4.5.6.China market size and forecast, by Treatment
7.4.5.7.China market size and forecast, by application
7.4.5.8.China market size and forecast, by end user
7.4.5.9.India
7.4.5.10.India market size and forecast, by Treatment
7.4.5.11.India market size and forecast, by application
7.4.5.12.India market size and forecast, by end user
7.4.5.13.Australia
7.4.5.14.Australia market size and forecast, by Treatment
7.4.5.15.Australia market size and forecast, by application
7.4.5.16.Australia market size and forecast, by end user
7.4.5.17.South Korea
7.4.5.18.South Korea market size and forecast, by Treatment
7.4.5.19.South Korea market size and forecast, by application
7.4.5.20.South Korea market size and forecast, by end user
7.4.5.21.Rest of Asia-Pacific
7.4.5.22.Rest of Asia-Pacific market size and forecast, by Treatment
7.4.5.23.Rest of Asia-Pacific market size and forecast, by application
7.4.5.24.Rest of Asia-Pacific market size and forecast, by end user
7.5.LAMEA
7.5.1.Key trends and opportunities
7.5.2.Market size and forecast, by Treatment
7.5.3.Market size and forecast, by application
7.5.4.Market size and forecast, by end user
7.5.5.Market size and forecast, by country
7.5.5.1.Brazil
7.5.5.2.Brazil market size and forecast, by Treatment
7.5.5.3.Brazil market size and forecast, by application
7.5.5.4.Brazil market size and forecast, by end user
7.5.5.5.Saudi Arabia
7.5.5.6.Saudi Arabia market size and forecast, by Treatment
7.5.5.7.Saudi Arabia market size and forecast, by application
7.5.5.8.Saudi Arabia market size and forecast, by end user
7.5.5.9.South Africa
7.5.5.10.South Africa market size and forecast, by Treatment
7.5.5.11.South Africa market size and forecast, by application
7.5.5.12.South Africa market size and forecast, by end user
7.5.5.13.Rest of LAMEA
7.5.5.14.Rest of LAMEA market size and forecast, by Treatment
7.5.5.15.Rest of LAMEA market size and forecast, by application
7.5.5.16.Rest of LAMEA market size and forecast, by end user
CHAPTER 8:COMPANY PROFILES
8.1.Alimera Sciences Inc.
8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Business performance
8.1.6.Key strategic moves and developments
8.2.Abbvie Inc.
8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio
8.2.5.Business performance
8.2.6.Key strategic moves and developments
8.3.Bausch Health Companies Inc.
8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Business performance
8.3.6.Key strategic moves and developments
8.4.Bayer AG
8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance
8.4.6.Key strategic moves and developments
8.5.F. Hoffmann-La Roche Ltd
8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.4 Business performance
8.5.5.Key strategic moves and developments
8.6.GlaxoSmithKline Plc
8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance
8.7.Kubota Pharmaceutical Hodlings Co. Ltd.
8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Key strategic moves and developments
8.8.Novartis AG
8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.8.6.Key strategic moves and developments
8.9.Regeneron Pharmaceuticals Inc.
8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Business performance
8.9.6.Key strategic moves and developments
8.10.Regen X Bio Inc.
8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Product portfolio
8.10.4.Business performance
8.10.5.Key strategic moves and developments
TABLE 01.MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT TYPE, 2020–2030($MILLION)
TABLE 02.MACULAR EDEMA AND MACULAR DEGENERATION MARKET FOR DRUG THERAPY, BY REGION, 2020–2030($MILLION)
TABLE 03.MACULAR EDEMA AND MACULAR DEGENERATION MARKET FOR LASER TREATMENT, BY REGION, 2020–2030 ($MILLION)
TABLE 04.MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 05.MACULAR EDEMA AND MACULAR DEGENERATION MARKET FOR MACULAR EDEMA, BY REGION, 2020–2030 ($MILLION)
TABLE 06.MACULAR EDEMA AND MACULAR DEGENERATION MARKET FOR MACULAR DEGENERATION, BY REGION, 2020–2030 ($MILLION)
TABLE 07.MACULAR EDEMA AND MACULAR DEGENERATIONMARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 08.MACULAR EDEMA AND MACULAR DEGENERATION MARKET FOR HOSPITALS, BY REGION, 2020–2030 ($MILLION)
TABLE 09.MACULAR EDEMA AND MACULAR DEGENERATION MARKET FOR CLINICS, BY REGION, 2020–2030 ($MILLION)
TABLE 10.MACULAR EDEMA AND MACULAR DEGENERATION MARKET FOR OTHERS, BY REGION, 2020–2030 ($MILLION)
TABLE 11.MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 12.NORTH AMERICA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 13.NORTH AMERICA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 14.NORTH AMERICA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 15.NORTH AMERICA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 16.U.S. MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 17.U.S. MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 18.U.S. MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 19.CANADA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 20.CANADA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 21.CANADA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 22.MEXICO MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 23.MEXICO MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 24.MEXICO MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 25.EUROPE MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 26.EUROPE MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 27.EUROPE MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 28.EUROPE MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 29.GERMANY MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 30.GERMANY MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 31.GERMANY MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 32.FRANCE MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 33.FRANCE MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 34.FRANCE MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 35.UK MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 36.UK MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 37.UK MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 38.ITALY MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 39.ITALY MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 40.ITALY MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 41.SPAIN MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 42.SPAIN MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 43.SPAIN MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 44.REST OF EUROPE MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 45.REST OF EUROPE MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 46.REST OF EUROPE MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 47.ASIA-PACIFIC MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 48.ASIA-PACIFIC MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 49.ASIA-PACIFIC MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 50.ASIA-PACIFIC MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 51.JAPAN MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 52.JAPAN MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 53.JAPAN MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 54.CHINA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 55.CHINA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 56.CHINA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 57.INDIA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 58.INDIA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 59.INDIA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 60.AUSTRALIA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 61.AUSTRALIA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 62.AUSTRALIA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 63.SOUTH KOREA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 64.SOUTH KOREA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 65.SOUTH KOREA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 66.REST OF ASIA-PACIFIC MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 67.REST OF ASIA-PACIFIC MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 68.REST OF ASIA-PACIFIC MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 69.LAMEA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 70.LAMEA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 71.LAMEA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 72.LAMEA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 73.BRAZIL MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 74.BRAZIL MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 75.BRAZIL MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 76.SAUDI ARABIA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 77.SAUDI ARABIA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 78.SAUDI ARABIA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 79.SOUTH AFRICA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 80.SOUTH AFRICA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 81.SOUTH AFRICA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 82.REST OF LAMEA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 83.REST OF LAMEA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 84.REST OF LAMEA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 85.ALIMERA SCIENCES: COMPANY SNAPSHOT
TABLE 86.ALIMERA SCIENCES: OPERATING SEGMENTS
TABLE 87.ALIMERA SCIENCES: PRODUCT PORTFOLIO
TABLE 88.ALIMERA SCIENCES: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 89.ABBVIE: COMPANY SNAPSHOT
TABLE 90.ABBVIE: OPERATING SEGMENTS
TABLE 91.ABBVIE: PRODUCT PORTFOLIO
TABLE 92.ABBVIE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 93.BAUSCH HEALTH: COMPANY SNAPSHOT
TABLE 94.BAUSCH HEALTH: OPERATING SEGMENTS
TABLE 95.BASUCH HEALTH: PRODUCT PORTFOLIO
TABLE 96.BAUSCH HEALTH: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 97.BAYER: COMPANY SNAPSHOT
TABLE 98.BAYER: OPERATING SEGMENTS
TABLE 99.BAYER: PRODUCT PORTFOLIO
TABLE 100.BAYER: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 101.ROCHE: COMPANY SNAPSHOT
TABLE 102.ROCHE: OPERATING SEGMENTS
TABLE 103.ROCHE: PRODUCT PORTFOLIO
TABLE 104.ROCHE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 105.GSK : PRODUCT PORTFOLIO
TABLE 106.GSK: OPERATING SEGMENTS
TABLE 107.GSK : PRODUCT PORTFOLIO
TABLE 108.KUBOTA: COMPANY SNAPSHOT
TABLE 109.KUBOTA: OPERATING SEGMENTS
TABLE 110.KUBOTA: PRODUCT PORTFOLIO
TABLE 111.KUBOTA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 112.NOVARTIS : OPERATING SEGMENTS
TABLE 113.NOVARTIS : PRODUCT PROTFOLIO
TABLE 114.NOVARTIS: KEY STRAGIC MOVES AND DEVELOPMENTS
TABLE 115.REGENERON: COMPANY SNAPSHOT
TABLE 116.REGENERON: OPERATING SEGMENTS
TABLE 117.REGENERON: PRODUCT PORTFOLIO
TABLE 118.REGENERON: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 119.REGEN X BIO: COMPANY SNAPSHOT
TABLE 120.REGEN X BIO: PRODUCT PORTFOLIO
TABLE 121.REGEN X BIO : KEY STRATEGIC MOVES AND DEVELOPMENTS
Similar Reports
Biomaterials are materials of either synthetic or natural origin that are used for interaction with biological systems for medical purposes such as treating or repairing damage tissues. They are used in joint replacements, plastic surgeries, drug delivery devi...
- Publish Date: September 1, 2016
- $5370
The global DNA sequencing market was estimated to be $6,243 million in 2017 and is projected to reach $25,470 million in 2025 growing with a CAGR of 19% from 2018 to 2025. DNA sequencing is a type of technology in which several DNA strands can be sequenced through massive parallelization. The DNA sequencing contains both Sanger’s method of sequencing and non-Sanger’s methods of sequencing. ...
- Publish Date: May 24, 2017
- $5370
Patients with serious nervous system injuries or strokes often require lifelong assistance, which burdens patients, their families, and society. Innovative, paradigm shifting strategies are required to develop treatments for neurological injury. Early dia...
- Publish Date: May 24, 2017
- $5370
